HB1801
- Generic Name
- HB1801
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 3
Recruiting
- Conditions
- Early or Locally Advanced HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT06747338
- Locations
- 🇨🇳
Clinical Trials Information Group, Shanghai, China
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Phase 1
Not yet recruiting
- Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Squamous Cell Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 534
- Registration Number
- NCT06319313
A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05863325
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, Jilin, China
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3
Not yet recruiting
- Conditions
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 880
- Registration Number
- NCT05838066
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04931823
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath